Free Trial

Zai Lab (ZLAB) Competitors

Zai Lab logo
$35.66 +0.72 (+2.06%)
Closing price 07/9/2025 04:00 PM Eastern
Extended Trading
$34.75 -0.91 (-2.55%)
As of 07:14 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ZLAB vs. SMMT, ITCI, GMAB, RDY, QGEN, VTRS, ASND, MRNA, BBIO, and BPMC

Should you be buying Zai Lab stock or one of its competitors? The main competitors of Zai Lab include Summit Therapeutics (SMMT), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Qiagen (QGEN), Viatris (VTRS), Ascendis Pharma A/S (ASND), Moderna (MRNA), BridgeBio Pharma (BBIO), and Blueprint Medicines (BPMC). These companies are all part of the "pharmaceutical products" industry.

Zai Lab vs. Its Competitors

Summit Therapeutics (NASDAQ:SMMT) and Zai Lab (NASDAQ:ZLAB) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, media sentiment, profitability, analyst recommendations, risk and valuation.

In the previous week, Summit Therapeutics had 2 more articles in the media than Zai Lab. MarketBeat recorded 14 mentions for Summit Therapeutics and 12 mentions for Zai Lab. Summit Therapeutics' average media sentiment score of 0.46 beat Zai Lab's score of 0.44 indicating that Summit Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Summit Therapeutics
4 Very Positive mention(s)
2 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Zai Lab
4 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

4.6% of Summit Therapeutics shares are owned by institutional investors. Comparatively, 41.7% of Zai Lab shares are owned by institutional investors. 84.9% of Summit Therapeutics shares are owned by insiders. Comparatively, 5.0% of Zai Lab shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summit Therapeutics has higher earnings, but lower revenue than Zai Lab. Summit Therapeutics is trading at a lower price-to-earnings ratio than Zai Lab, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Summit Therapeutics$700K26,248.08-$221.32M-$0.34-72.76
Zai Lab$398.99M9.93-$257.10M-$2.49-14.32

Summit Therapeutics has a beta of -1.01, suggesting that its share price is 201% less volatile than the S&P 500. Comparatively, Zai Lab has a beta of 0.99, suggesting that its share price is 1% less volatile than the S&P 500.

Summit Therapeutics currently has a consensus price target of $34.67, indicating a potential upside of 40.12%. Zai Lab has a consensus price target of $54.28, indicating a potential upside of 52.20%. Given Zai Lab's stronger consensus rating and higher probable upside, analysts clearly believe Zai Lab is more favorable than Summit Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Summit Therapeutics
2 Sell rating(s)
0 Hold rating(s)
11 Buy rating(s)
1 Strong Buy rating(s)
2.79
Zai Lab
0 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.80

Summit Therapeutics has a net margin of 0.00% compared to Zai Lab's net margin of -60.26%. Zai Lab's return on equity of -33.35% beat Summit Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Summit TherapeuticsN/A -62.87% -51.61%
Zai Lab -60.26%-33.35%-23.28%

Summary

Summit Therapeutics beats Zai Lab on 9 of the 17 factors compared between the two stocks.

Get Zai Lab News Delivered to You Automatically

Sign up to receive the latest news and ratings for ZLAB and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZLAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ZLAB vs. The Competition

MetricZai LabMED IndustryMedical SectorNASDAQ Exchange
Market Cap$3.88B$2.90B$5.51B$8.95B
Dividend YieldN/A2.44%5.25%4.04%
P/E Ratio-14.3221.0128.0220.16
Price / Sales9.93246.40405.99173.08
Price / CashN/A41.8337.0657.97
Price / Book4.647.868.125.62
Net Income-$257.10M-$54.96M$3.16B$248.50M
7 Day Performance-2.11%5.27%3.14%4.49%
1 Month Performance-10.85%3.78%3.48%7.03%
1 Year Performance109.15%5.85%34.05%21.07%

Zai Lab Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ZLAB
Zai Lab
3.2812 of 5 stars
$35.66
+2.1%
$54.28
+52.2%
+114.6%$3.88B$398.99M-14.321,869Gap Up
SMMT
Summit Therapeutics
2.492 of 5 stars
$21.28
+3.3%
$35.09
+64.9%
+215.6%$15.30B$700K-62.59110
ITCI
Intra-Cellular Therapies
0.7364 of 5 stars
$131.87
flat
$109.70
-16.8%
N/A$14.05B$680.50M-151.57560
GMAB
Genmab A/S
4.1595 of 5 stars
$20.66
+0.8%
$37.60
+82.0%
-15.8%$13.15B$3.12B11.742,682News Coverage
Positive News
Analyst Forecast
RDY
Dr. Reddy's Laboratories
2.8028 of 5 stars
$15.03
-0.3%
$16.95
+12.8%
-5.1%$12.58B$3.81B22.7727,811
QGEN
Qiagen
3.8904 of 5 stars
$48.07
+0.6%
$49.40
+2.8%
+23.3%$10.62B$1.98B120.525,765
VTRS
Viatris
2.6695 of 5 stars
$8.93
-0.9%
$10.40
+16.5%
-14.5%$10.57B$14.74B-2.8232,000
ASND
Ascendis Pharma A/S
3.5035 of 5 stars
$172.60
+0.2%
$220.67
+27.8%
+28.8%$10.53B$393.54M-27.481,017
MRNA
Moderna
4.4673 of 5 stars
$27.59
+1.6%
$46.61
+68.9%
-71.7%$10.50B$3.24B-3.165,800
BBIO
BridgeBio Pharma
4.6896 of 5 stars
$43.18
-3.7%
$58.85
+36.3%
+78.9%$8.52B$221.90M-12.23400Analyst Upgrade
Gap Up
High Trading Volume
BPMC
Blueprint Medicines
1.5447 of 5 stars
$128.18
+0.1%
$128.06
-0.1%
+11.5%$8.27B$508.82M-51.89640Positive News
Insider Trade

Related Companies and Tools


This page (NASDAQ:ZLAB) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners